The FDA has approved mitomycin intravesical solution for certain patients with recurrent non-muscle invasive bladder cancer. The U.S. Food and Drug Administration (FDA) has approved mitomycin intravesical solution (Zusduri) for the treatment of adult...
The FDA has approved taletrectinib for certain patients with ROS1-mutated lung cancer. The U.S. Food and Drug Administration (FDA) has approved taletrectinib (Ibtrozi) for the treatment of adult patients with locally advanced or metastatic...
A blood test can detect breast cancer drug resistance, and a combination treatment improves outcomes in colorectal cancer.
The FDA has approved darolutamide for metastatic castration-sensitive prostate cancer. The U.S. Food and Drug Administration (FDA) has approved darolutamide (Nubeqa) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). Darolutamide is...
AI can help doctors determine which breast cancer patients qualify for targeted therapy, and cancer deaths among women have increased with rising temperatures in some countries.
This month, the editors of AACR’s journals picked studies highlighting genetic parallels between cancer evolution and high-altitude physiology, data linking oil and gas exposure to childhood leukemia risk, and more.
The AACR Annual Meeting 2025, held April 25-30, featured six Plenary Sessions that explored exciting areas of cancer research, including cancer evolution; KRAS, extrachromosomal DNA (ecDNA), and cancer vaccines; innovative technology advancing organoid models,...
The latest edition of From the Bench features creative cancer research, including making tumors seem like pig organs, starving cancer with fat, and more.
Disasters present a threat to cancer care, and understanding prostate cancer screening recommendations after President Joe Biden’s diagnosis.
At the AACR Annual Meeting 2025, researchers and patient advocates shared insights into the impact of NIH funding cuts on cancer research.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More